All News

This comes after a district court in Texas ruled to keep Mifepristone available, but with heavy restrictions.

Data was presented at the 44th National Association of Pediatric Nurse Practitioners Conference regarding the effectiveness of vaccines and antivirals in preventing life threatening conditions.

At the 44th National Association of Pediatric Nurse Practitioners Conference, a session presented data explaining why teenagers with T1D are at high risk for developing anorexia and bulimia.

At the 44th annual National Association of Pediatric Nurse Practitioners Conference, the CDC provided an updated immunization schedule that details new changes.

HHS Secretary Xavier Becerra will release an amendment to the declaration in the coming weeks.

Your weekly roundup of the latest news from Drug Topics®.

Over 400 pharmaceutical employees and executives signed an open letter in a show of solidarity with the FDA, but some say that big pharma’s actions helped lead to this moment in the first place.

A recent study showed a link between menopause and increased glaucoma risk, with estrogen-based treatment being a possible solution.

Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight when compared to semaglutide. But with a current list price of $1,023 for a one-month supply, is tirzepatide (Mounjaro; Lilly) worth it?

A new survey found that neither generation is particularly good at maintaining healthy sun habits, and have low skin cancer awareness.

Researchers of a new study investigated what's causing vaccine hesitancy, and why individuals are feeling vaccine fatigue.

GrayMatters Health plans to use its technology for other mental health indications in the future.

A new study examines whether anakinra can reduce inflammation and the need for mechanical ventilation in patients with severe COVID-19 pneumonia.

The FDA granted the EUA based on the phase 3 trial results that demonstrated vilobelimab's efficacy compared to placebo, with a 23.9% relative reduction in all-cause mortality from COVID-19 at 28 days.

A new study from JAPHA explores the link between OUD and social factors.

The FDA, state governors, and OB/GYN groups around the country are fighting back against Judge Matthew Kacsmaryk’s ruling.

The drug, called Atovaquone, has been voluntarily recalled due to possible Bacillus cereus contamination.

The FDA has finally decided to withdraw approval of Makena and its generics after Covis Pharma volunteered to remove the drug from market in March.

Data reveal 50% of meningitis vaccination appointments were delayed or canceled amid the COVID-19 pandemic, leading authors of a survey to highlight the need for “urgent action” to maintain routine vaccination levels among children.

Approximately 8000 to 9000 U.S. patients would be eligible for this combination, intended for patients with locally advanced or metastatic urothelial cancer (la/mUC).

Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken over 3 years on average to complete since 2012.

The biopharmaceutical company says it is “extremely disappointed” with the results of the COURAGE-ALS study, which failed to meet primary or secondary endpoints.

Off-label drug combinations are increasingly being used in cancer treatments, but there is the potential for overlapping or additive toxicities, explained a speaker at the 2023 HOPA Annual Conference.

Members of the Senate Finance Committee are pushing PBMs to modernize the rules regarding out of pocket costs and competition.

Masking, social distancing, and school closures all contributed to children being exposed to fewer environmental triggers of asthma.

In a recent trial, investigators found increased rates of screening when human papillomavirus (HPV) self-sampling kits were mailed to participants, and that this process costs less than usual care.

During a session at the 2023 HOPA Annual Conference, Rebecca Champion, PharmD, BCOP, highlighted new therapies in the market for hematologic malignancies with a focus on bispecific antibodies and chimeric antigen receptor T-cell therapies.

What's on the agenda for FTP in the upcoming month?

The ruling states that insurers and employers who run plans for employees will have a choice over how- and whether- to cover certain routine screenings, exams and tests.